01 — At a Glance
The Eye Specialist Nobody Knew Was Printing Money
- 52-Week High / Low₹6,392 / ₹3,750
- Q3 FY26 Sales₹116 Cr
- Q3 FY26 PAT₹17.3 Cr
- Annualised EPS₹35.76
- TTM EPS₹146
- Book Value / Share₹651
- Price to Book7.19x
- OPM (Q3)30%
- Total Facilities63 (AEHL)
- Surgeries Performed (FY25)62,000
Flash Summary: AEHL just posted Q3 PAT of ₹17.3 crore — up 66% YoY. Revenue grew 22%, earnings grew 66%. That gap is your Mojo Meter. The stock trades at 32.4x P/E with 29.5% ROE and a P/BV of 7.2x. The market says: “Beta hai lekin quality hai.” Your auditor says: “Beta? Yeh sab risk hai.” Somewhere in between is the truth.
02 — Introduction
The Eye Hospital That Learned to Print Cash While Others Counted Glasses
Let me paint you a picture. In 1994, Dr. Agarwal decided the Indian eye-care space needed an organized player. Spectacles were selling at street corners. Cataract surgeries happened in mohalla clinics where the surgeon’s definition of “sterile” was “we dusted it yesterday.”
Thirty years later, Dr. Agarwal’s Health Care Limited (AHCL) has become India’s largest eye-care services chain by revenue. The parent company. The boss. The one that went public in February 2025 and raised ₹300 crore like it was picking up spare change from the sofa.
Dr. Agarwal’s Eye Hospital Limited (AEHL) is the subsidiary. 63 facilities in Tamil Nadu and beyond. 230 doctors. 588,000 patients served in FY25. 62,000 surgeries. It’s the surgical wing — the money printer of the group. And now, the boards have decided: why have two listed entities when you can have one mega-entity printing money twice as fast?
The Q3 FY26 story has exactly three chapters. First: yet another quarter where PAT grew 66% while revenue grew 22%. (Translation: margins are expanding like a balloon in summer.) Second: the company announced it’s merging with its parent, AHCL. Subject to NCLT approval. Subject to shareholder approval. Subject to three more government approvals you’ve never heard of. Third: everyone’s wondering what the merger means. Accretion? Dilution? Will the queue in the doctor’s office get longer?
Merger Snapshot (Announced Aug 2025): For every 2 shares of AEHL you own, you’ll get 23 shares of AHCL. That’s a 15% premium to the 10-day VWAP. AHCL is also buying ₹70 crore worth of new AEHL shares at ₹5,270 per share for capex. Timeline: Merger expected by Q2 FY27 if all gods are appeased and all stamps are collected.
03 — Business Model: WTF Do They Even Do?
They Fix Eyes. And Apparently, That’s a Goldmine.
Members get full access to every article.
